AVLN 8-K
Avalyn Pharma Inc. (AVLN)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
On June 29, 2026 (the “Effective Date”), Avalyn Pharma Inc. (the “Company”) entered into a First Amendment to the Sublease (the “Sublease Amendment”), which amends that certain Sublease Agreement (the “Sublease Agreement”) with CRISPR Therapeutics, Inc. (the “Sublandlord”), dated as of August 29, 2025, providing for the lease of approximately 8,774 rentable square feet in the building located at 105 West First Street, Boston, Massachusetts (the “Premises”).
Pursuant to the Sublease Amendment, the Sublandlord and the Company, as Subtenant, have agreed to an expansion of the Premises from approximately 8,774 rentable square feet to approximately 13,708 rentable square feet as of the Effective Date.
Additionally, under the terms of the Sublease Amendment, the Company’s future minimum lease payments will increase by approximately $924,000 over the remaining lease term.
Except as modified by the Sublease Amendment, the terms of the Sublease Agreement remain in full force and effect.
The foregoing summary of the material terms of the Sublease Amendment does not purport to be a complete description and is qualified in its entirety by reference to the complete text of the Sublease Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
10.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
Avalyn Pharma Inc. |
|
|
|
|
Date: |
July 1, 2026 |
By: |
/s/ Lyn Baranowski |
|
|
|
Lyn Baranowski |
Exhibit 10.1
FIRST AMENDMENT TO SUBLEASE
THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is made and entered into as of June 29, 2026 (the “Effective Date”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation, with a place of business at 105 West First Street, Boston, MA 02127 (“Sublandlord”), and AVALYN PHARMA INC., a Delaware corporation with a place of business at 105 West First Street (“Subtenant”).
R e c i t a l s
NOW, THEREFORE, in consideration of the above recitals which by this reference are incorporated herein, the mutual covenants and conditions contained herein and other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Sublandlord and Subtenant agree as follows:
RENTAL PERIOD |
ANNUAL BASE RENT |
MONTHLY PAYMENT |
Expansion Premises Commencement Date – January 31, 2027 |
N/A |
$28,781.67 |
February 1, 2027 – January 31, 2028 |
$355,741.40 |
$29,645.12 |
February 1, 2028 – January 31, 2029 |
$366,413.64 |
$30,534.47 |
Page 2
[Signatures appear on following page(s).]
Page 3
IN WITNESS WHEREOF, Sublandlord and Subtenant execute this Amendment as of the date first written above.
[SUBLANDLORD] |
|
|
[SUBTENANT]
|
|
|||
CRISPR THERAPEUTICS, INC., a Delaware corporation, |
|
AVALYN PHARMA INC., a Delaware corporation
|
|||||
By: |
/s/ AJ Silver |
|
By: |
/s/ Adam Golden |
|||
Name: |
AJ Silver |
|
Name: |
Adam Golden |
|||
Its: |
SVP Finance |
|
Its: |
General Counsel |
|||
|
Hereunto Duly Authorized |
|
|
Hereunto Duly Authorized |
|||
Signature Page to Amendment to Sublease
EXHIBIT A
Expansion Premises
[***]
A-1
EXHIBIT B
Expansion Furniture Inventory
[***]
B-1